Ann: Lumos Appoints Henry Schein as US Distributor for FebriDx, page-135

From my sarcasm pocket.

Fact is, product just being sold in US now and is ramping up - increase in revenues could be beneficial to short term share price. We are still awaiting CLIA waiver for the product which would expand reach from 10,000 labs to 200,000 GP offices. There could be another major distributor announcement for Febridx in the US as indicated in the last webinar.

Any further positive deals / expansion etc could improve the sp in the short term.

We are at the bottom of the barrel for volume which means retail are really in control here. Until news comes out (next quarterly) the SP unlikely to move as the TA wont really change much without volume either.